Xiao Yongzhen, Muhammad Ishaq, Ma Xianpeng, Yu Huajun, Yan Shikai, Xiao Xue, Jin Huizi
Department of Natural Product Chemistry, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Guizhou Jingcheng Pharmaceutical Co., Ltd., Guiyang 550200, China.
Chin Herb Med. 2022 Sep 17;14(4):638-642. doi: 10.1016/j.chmed.2021.09.016. eCollection 2022 Oct.
To isolate and identify the undescribed compounds from the fruits of and evaluate its nitric oxide inhibition potential.
The chromatographic techniques of silica gel, Sephadex, and HPLC were used for isolation and purification of the compounds, while HR-ESI-MS, 1D NMR, 2D NMR, ECD, and X-ray diffraction techniques were used to characterize and confirm the isolated compounds. Moreover, the anti-inflammatory activity of the isolated compounds was carried out to check inhibitory potential against the production of nitric oxide with RAW264.7 cells stimulated by LPS.
Camganoid A (), a novel sesquiterpene possessing an unprecedented skeleton, and camganoid B (), containing a unique eight-membered sesquiterpene moiety with a new carbon skeleton, were isolated and identified from the fruits of The absolute configurations of and were confirmed by single crystal X-ray diffraction and electronic circular dichroism (ECD) calculations. Among these compounds, compound exhibited potent inhibitory activity against the production of nitric oxide with IC value of 4.59 μmol/L in RAW264.7 cells stimulated by LPS.
The isolation of two new skeletons from the fruits part of possessed unique skeletons which have not been reported before.
从[植物名称]果实中分离并鉴定未描述的化合物,并评估其一氧化氮抑制潜力。
采用硅胶、葡聚糖凝胶和高效液相色谱等色谱技术对化合物进行分离和纯化,同时利用高分辨电喷雾电离质谱、一维核磁共振、二维核磁共振、电子圆二色光谱和X射线衍射技术对分离得到的化合物进行表征和确认。此外,对分离得到的化合物进行抗炎活性研究,以检测其对脂多糖刺激的RAW264.7细胞产生一氧化氮的抑制潜力。
从[植物名称]果实中分离并鉴定出了camganoid A([具体结构]),一种具有前所未有的骨架的新型倍半萜,以及camganoid B([具体结构]),其含有一个具有新碳骨架的独特八元倍半萜部分。通过单晶X射线衍射和电子圆二色光谱(ECD)计算确定了camganoid A和camganoid B的绝对构型。在这些化合物中,化合物[具体编号]在脂多糖刺激的RAW264.7细胞中对一氧化氮的产生表现出强效抑制活性,IC50值为4.59 μmol/L。
从[植物名称]果实部分分离出的两个新骨架具有独特的骨架结构,此前未见报道。